Whole-course Concurrent and Adjuvant Nivolumab Combined with Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03984357, Cancer Cell, 2025,已接收)
Adjuvant PD-1 Antibody in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (NCT03427827, JAMA, 2025,已接收)
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (NCT06455410, 进行中)
Individualized Elective Neck Irradiation in NPC Patients (NCT06241612, 进行中)
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (NCT06239727, 进行中)
Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT05587374, 进行中)
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05563480, completed)
Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NPC-LN) (NCT05389306, 进行中)
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (NCT05342792, 进行中)
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) (NCT05044117, 进行中) 本帖最后由 school 于 2025-2-21 07:35 编辑
maicon08 发表于 2025-2-21 00:22
马骏院士团队被接收一篇JAMA、一篇Cancer Cell，另有8项临床试验在进行中
Whole-course Concurrent and Adj ...
中肿不讲武德，太霸道了 除了评院士，中山医实力妥妥第一梯队 随着CA放开发表临床研究，接下来肿瘤领域强校协和、复旦和北大预计也会在CA发文，整体实力一般但单点爆破能力超强的上交（陆舜）、南方医（吴一龙）、同济（周彩存）也有机会 maicon08 发表于 2025-2-21 15:49
随着CA放开发表临床研究，接下来肿瘤领域强校协和、复旦和北大预计也会在CA发文，整体实力一般但单点爆破能 ...
期望吴一龙校友能成为下一个，也发表一篇CA。。。。:loveliness:
页:
1
[2]